- Conditions
- Neoplasms
- Interventions
- DSP-0337
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 4
- States / cities
- Indianapolis, Indiana • Detroit, Michigan • San Antonio, Texas + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 219
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Schizophrenia
- Interventions
- Lurasidone
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 38
- States / cities
- Little Rock, Arkansas • Cerritos, California • Downey, California + 31 more
- Conditions
- Neoplasms
- Interventions
- DSP-0509, DSP-0509, Pembrolizumab
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 5
- States / cities
- Indianapolis, Indiana • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 2 more
- Conditions
- Major Depressive Disorder With Mixed Features
- Interventions
- Lurasidone, Placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 211 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Escondido, California • Garden Grove, California + 15 more
- Conditions
- Glioblastoma
- Interventions
- BBI608, Temozolomide
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
- Interventions
- Biospecimen Collection, Contrast Agent, Leuprolide, Magnetic Resonance Imaging, Physical Performance Testing, Relugolix
- Procedure · Other · Drug
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- BBI608, Nab-paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, Fluorouracil, MM-398
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Atlanta, Georgia • Fort Wayne, Indiana + 9 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Arformoterol tartrate, Placebo: Normal Saline, Treadmill Exercise, Cycle Exercise
- Drug · Other
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Schizophrenia
- Interventions
- Lurasidone HCl
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Culver City, California
- Conditions
- Asthma
- Interventions
- Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI, Racemic Albuterol followed by levalbuterol HFA MDI
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 4
- States / cities
- Encinitas, California • Los Angeles, California • North Dartmouth, Massachusetts + 1 more
- Conditions
- Binge Eating Disorder
- Interventions
- dasotraline 4mg, dasotraline 6mg, Placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 491 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Encino, California + 44 more
- Conditions
- Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
- Interventions
- arformoterol, Salmeterol
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 35 Years and older
- Enrollment
- 799 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 90
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 77 more
- Conditions
- Cancer, Advanced Solid Tumors
- Interventions
- BBI503
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 311 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 18
- States / cities
- Scottsdale, Arizona • Denver, Colorado • Indianapolis, Indiana + 12 more
- Conditions
- Primary Insomnia
- Interventions
- Eszopiclone, Placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 21 Years to 64 Years
- Enrollment
- 830 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 58
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 55 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- BBI608, BBI503, Sorafenib
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 29
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Coronado, California + 25 more
- Conditions
- Parkinson Disease
- Interventions
- APL-130277
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 496 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 42 more
- Conditions
- Parkinson's Disease, Off Episodes of Parkinson Disease
- Interventions
- APL-130277, Placebo, Moxifloxacin
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • Fountain Valley, California + 7 more
- Conditions
- Schizophrenia
- Interventions
- DSP-1349M, placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Long Beach, California
- Conditions
- Obstructive Sleep Apnea
- Interventions
- Eszopiclone, Placebo control
- Drug
- Lead sponsor
- Walter Reed Army Medical Center
- Federal
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Adult Attention Deficit Hyperactivity Disorder
- Interventions
- SEP-225289, Placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 341 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 31
- States / cities
- Encino, California • Garden Grove, California • Irvine, California + 28 more
- Conditions
- Depressive Episodes, Bipolar I Depression
- Interventions
- SEP-4199 CR 200 mg, SEP-4199 CR 400 mg, Placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 34
- States / cities
- Huntsville, Alabama • Bryant, Arkansas • Anaheim, California + 30 more
- Conditions
- Binge Eating Disorder
- Interventions
- Dasotraline, Placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 319 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 43
- States / cities
- Beverly Hills, California • Encino, California • Garden Grove, California + 39 more
- Conditions
- Restless Legs Syndrome
- Interventions
- Apomorphine Sublingual Film, Placebo
- Drug
- Lead sponsor
- William Ondo, MD
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Advanced Gastrointestinal Cancer
- Interventions
- BBI608, Fluorouracil, Oxaliplatin, Leucovorin, Irinotecan, Bevacizumab, Capecitabine, Regorafenib
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 495 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Fort Myers, Florida • Atlanta, Georgia + 11 more